Translational relevance
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A major hurdle in the treatment of metastatic renal cell carcinoma (RCC) is the lack of 2 therapeutic agents that can induce durable complete remission without causing systemic 3 toxicities. In this study, we achieved complete elimination of established metastatic RCC in The utilization of MSCs as a delivery vehicle allowed site-specific secretion of therapeutic enable target-specific delivery of therapeutic agents (8) , which can be especially beneficial replicative oncolytic adenovirus (11) were utilized to generate tumor site-specific antitumor 7 effects in subcutaneous and orthotopic xenograft models, respectively. 
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One potential drawback of this strategy is that it fails to destroy slow-proliferating or 13 quiescent tumor cell population, which may cause tumor recurrence. In order to achieve for eliciting full biological activity of agents (18) . Another strategy to enhance therapeutic 5 effects of TRAIL is the addition of other treatment modalities for combination therapy. A 6 previous study showed that the combination of agonistic anti-TRAIL receptor antibody with 
13
In the present study, we analyzed the therapeutic effects of MSC-mediated 
Adenoviruses and transduction
10
The DNA sequences encoding dodecameric TRAIL (dTRAIL), tissue plasminogen To evaluate GCV cytotoxicity on engineered MSCs, various concentrations of GCV 10 (0, 10, 30, and 100 μM) were used to treat MSC/dTRAIL-TK, MSC/dTRAIL, MSC/TK, and 11 MSC/mock. Cell viability was measured at day 0, 1, 3, 5, and 7 and percent survival was 12 calculated as described above. injection, and then various organs (lung, liver, spleen, heart, kidney, and brain) were isolated.
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Each organ was minced, treated with collagenase, and prepared for flow cytometric analysis. All data were expressed as averages ± standard error means. To measure the statistical 17 differences between groups, a two-tailed Student's t-test was used. For all statistical tests, a 18 P-value of < 0.05 was considered to be statistically significant. To investigate the effects of the dodecamerization of TRAIL on its apoptosis-inducing 4 activity, we generated rAd expressing either dodecameric TRAIL (dTRAIL) or trimeric 5 TRAIL (tTRAIL), as described in Materials and Methods (Fig. 1A) . The expressions of 6 dTRAIL and tTRAIL protein from transduced MSCs were confirmed by Western blot (Fig.   7 1B). When MSCs were transduced with rAd/dTRAIL or rAd/tTRAIL, the inclusion of ferric
) significantly enhanced the expression of both dTRAIL and tTRAIL by 10 to 100 9 fold. The amount of secreted TRAIL from MSC/dTRAIL in culture supernatant was about 3-10 fold higher than that from MSC/tTRAIL (Fig. 1C) . As the titer of rAd increased, the 11 expression levels of TRAIL also increased, but the viability of MSCs was negatively affected 12 by the viral doses of greater than 100 MOI (Fig. 1D) . Decreased MSC viability was unlikely 
Fe
3+ was determined to be the optimal condition for MSC transduction, which did not affect 18 the phenotype of MSCs (Supplementary Fig. 1 ).
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To examine the cytotoxic effects of TRAIL-expressing MSCs on tumor cells, CFSE- Fig. 2) . (Fig. 2C) .
21
To investigate whether the combination of dTRAIL and HSV-TK could exhibit 
were co-cultured with RENCA cells for 48 hours and treated with 100 μM of GCV for 1 additional 48 or 72 hours. At both time-points, MSC/dTRAIL-TK exhibited stronger 2 apoptotic effects than the sum of effects from MSC/TK and MSC/dTRAIL in RENCA cells 3 (Fig. 3A) . It is also worth noting that decreasing the number of MSC/dTRAIL-TK by 75% in (Fig. 3B) . To investigate the molecular mechanisms involved 9 in the combinatory action of dTRAIL and HSV-TK, we analyzed the expression levels of 10 apoptosis-related signaling molecules, including caspase-3, caspase-8, cytochrome c, and 11 poly (ADP-ribose) polymerase (PARP). Expression levels of all the molecules tested were 12 significantly increased by co-expression of dTRAIL and HSV-TK (Fig. 3C) , which is (Fig. 4A) . In addition, a higher frequency of naïve or (Fig. 4C) . Similar results were reported by a previous report that examined the homing 11 of syngeneic MSCs in mice bearing Renca pulmonary metastasis. In this study, histological 12 analysis of lungs showed that MSCs tended to surround tumor nodules when their diameter is 13 large and infiltrate nodules when the diameter is small (27). Although xenogeneic MSCs were 14 used in our experimental system, cells that reached the tumor nodules seemed to survive 15 longer than those did not, as suggested by the report mentioned above.
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Next, we aimed to optimize the time-points for GCV and engineered MSC treatment to 17 maximize the therapeutic efficacy. Firstly, we treated mice with GCV on day 0, 1, 2, or 3 after 18 MSC/dTRAIL-TK injection and analyzed the number of metastatic tumor nodules at 14 days 19 after tumor injection. GCV treatment that was initiated on the same day with MSC/dTRAIL-20 TK administration induced moderate antitumor effects, presumably due to rapid MSC killing 21 (Fig. 5A) . On the other hand, GCV treatment initiated on day 2 maximized the combinatory (Fig. 5B) . However, although statistically 7 insignificant, MSC/dTRAIL-TK therapy on day 7 achieved more than 90% regression, 8 showing superior antimetastatic effects compared to day 1 therapy. Therefore, engineered 9 MSC administration was started on day 7 after tumor injection for the following in vivo 10 experiments.
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After optimizing GCV and engineered MSC treatment time-points, therapeutic efficacy 
of durable complete remission. The optimal time points for in vivo application of GCV and 1 MSCs were empirically determined to provide the maximum therapeutic efficacy. We then 2 evaluated the effects of biological doses and frequency of administration on tumor regression. 
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In conclusion, sequential administration of MSCs co-expressing dTRAIL and TK is a CCR-12-1568 at the tumor site to increase the availability of therapy. Moreover, the incorporation of HSV-1 TK/GCV system enables efficient elimination of MSCs, lowering the risk of malignant 2 transformation of infused MSCs. Overall, our findings propose a novel therapeutic approach 3 to achieve durable complete remission in metastatic RCC. were intravenously injected on day 7 after tumor injection, and then GCV treatment was 12 initiated on day 0, 1, 2, or 3 after MSC injections for 7 consecutive days. The numbers of 13 metastatic tumor nodules in the lung were counted on day 14 after tumor injection (n = 10). 14 (B) Engineered MSCs were intravenously injected on day 1 or day 7 post tumor injection 15 (PTI), and then GCV was treated for 7 days, starting on day 2 after MSC injection. The 16 number of metastatic tumor nodules in the lung was counted on day 14 after tumor injection 17 (n = 11). Representative pictures of lungs (therapy on day 7 PTI) are shown. **p < 0.01. (C) 18 Engineered MSCs were injected on day 7 after tumor injection, and then GCV was treated for 
